vs

Side-by-side financial comparison of MYR GROUP INC. (MYRG) and Revvity (RVTY). Click either name above to swap in a different company.

MYR GROUP INC. is the larger business by last-quarter revenue ($973.5M vs $772.1M, roughly 1.3× Revvity). Revvity runs the higher net margin — 12.7% vs 3.8%, a 9.0% gap on every dollar of revenue. On growth, MYR GROUP INC. posted the faster year-over-year revenue change (17.3% vs 5.9%). Revvity produced more free cash flow last quarter ($161.8M vs $84.9M). Over the past eight quarters, MYR GROUP INC.'s revenue compounded faster (9.3% CAGR vs 9.0%).

MYR Group Inc. is an American corporation that offers electrical construction services for transmission and distribution lines, substations, commercial and industrial buildings, and renewable energy. It is the parent company to 12 subsidiary electrical construction companies.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

MYRG vs RVTY — Head-to-Head

Bigger by revenue
MYRG
MYRG
1.3× larger
MYRG
$973.5M
$772.1M
RVTY
Growing faster (revenue YoY)
MYRG
MYRG
+11.5% gap
MYRG
17.3%
5.9%
RVTY
Higher net margin
RVTY
RVTY
9.0% more per $
RVTY
12.7%
3.8%
MYRG
More free cash flow
RVTY
RVTY
$76.9M more FCF
RVTY
$161.8M
$84.9M
MYRG
Faster 2-yr revenue CAGR
MYRG
MYRG
Annualised
MYRG
9.3%
9.0%
RVTY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MYRG
MYRG
RVTY
RVTY
Revenue
$973.5M
$772.1M
Net Profit
$36.5M
$98.4M
Gross Margin
11.4%
Operating Margin
4.8%
14.5%
Net Margin
3.8%
12.7%
Revenue YoY
17.3%
5.9%
Net Profit YoY
129.1%
3.9%
EPS (diluted)
$2.33
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYRG
MYRG
RVTY
RVTY
Q4 25
$973.5M
$772.1M
Q3 25
$950.4M
$698.9M
Q2 25
$900.3M
$720.3M
Q1 25
$833.6M
$664.8M
Q4 24
$829.8M
$729.4M
Q3 24
$888.0M
$684.0M
Q2 24
$828.9M
$691.7M
Q1 24
$815.6M
$649.9M
Net Profit
MYRG
MYRG
RVTY
RVTY
Q4 25
$36.5M
$98.4M
Q3 25
$32.1M
$46.7M
Q2 25
$26.5M
$53.9M
Q1 25
$23.3M
$42.2M
Q4 24
$16.0M
$94.6M
Q3 24
$10.6M
$94.4M
Q2 24
$-15.3M
$55.4M
Q1 24
$18.9M
$26.0M
Gross Margin
MYRG
MYRG
RVTY
RVTY
Q4 25
11.4%
Q3 25
11.8%
53.6%
Q2 25
11.5%
54.5%
Q1 25
11.6%
56.5%
Q4 24
10.4%
Q3 24
8.7%
56.3%
Q2 24
4.9%
55.7%
Q1 24
10.6%
54.6%
Operating Margin
MYRG
MYRG
RVTY
RVTY
Q4 25
4.8%
14.5%
Q3 25
4.9%
11.7%
Q2 25
4.4%
12.6%
Q1 25
4.1%
10.9%
Q4 24
3.6%
16.3%
Q3 24
2.3%
14.3%
Q2 24
-2.5%
12.4%
Q1 24
3.0%
6.8%
Net Margin
MYRG
MYRG
RVTY
RVTY
Q4 25
3.8%
12.7%
Q3 25
3.4%
6.7%
Q2 25
2.9%
7.5%
Q1 25
2.8%
6.4%
Q4 24
1.9%
13.0%
Q3 24
1.2%
13.8%
Q2 24
-1.8%
8.0%
Q1 24
2.3%
4.0%
EPS (diluted)
MYRG
MYRG
RVTY
RVTY
Q4 25
$2.33
$0.86
Q3 25
$2.05
$0.40
Q2 25
$1.70
$0.46
Q1 25
$1.45
$0.35
Q4 24
$0.97
$0.77
Q3 24
$0.65
$0.77
Q2 24
$-0.91
$0.45
Q1 24
$1.12
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYRG
MYRG
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$150.2M
$919.9M
Total DebtLower is stronger
$59.0M
Stockholders' EquityBook value
$660.4M
$7.3B
Total Assets
$1.6B
$12.2B
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYRG
MYRG
RVTY
RVTY
Q4 25
$150.2M
$919.9M
Q3 25
$76.2M
$931.4M
Q2 25
$23.0M
$991.8M
Q1 25
$10.9M
$1.1B
Q4 24
$3.5M
$1.2B
Q3 24
$7.6M
$1.2B
Q2 24
$1.9M
$2.0B
Q1 24
$3.9M
$1.7B
Total Debt
MYRG
MYRG
RVTY
RVTY
Q4 25
$59.0M
Q3 25
$72.0M
Q2 25
$86.1M
Q1 25
$87.2M
Q4 24
$74.4M
Q3 24
$93.2M
Q2 24
$45.1M
Q1 24
$37.9M
Stockholders' Equity
MYRG
MYRG
RVTY
RVTY
Q4 25
$660.4M
$7.3B
Q3 25
$617.6M
$7.4B
Q2 25
$583.2M
$7.6B
Q1 25
$548.7M
$7.6B
Q4 24
$600.4M
$7.7B
Q3 24
$588.5M
$7.9B
Q2 24
$633.3M
$7.9B
Q1 24
$663.7M
$7.8B
Total Assets
MYRG
MYRG
RVTY
RVTY
Q4 25
$1.6B
$12.2B
Q3 25
$1.6B
$12.1B
Q2 25
$1.6B
$12.4B
Q1 25
$1.5B
$12.4B
Q4 24
$1.6B
$12.4B
Q3 24
$1.6B
$12.8B
Q2 24
$1.6B
$13.4B
Q1 24
$1.6B
$13.4B
Debt / Equity
MYRG
MYRG
RVTY
RVTY
Q4 25
0.09×
Q3 25
0.12×
Q2 25
0.15×
Q1 25
0.16×
Q4 24
0.12×
Q3 24
0.16×
Q2 24
0.07×
Q1 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYRG
MYRG
RVTY
RVTY
Operating Cash FlowLast quarter
$114.8M
$182.0M
Free Cash FlowOCF − Capex
$84.9M
$161.8M
FCF MarginFCF / Revenue
8.7%
21.0%
Capex IntensityCapex / Revenue
3.1%
2.6%
Cash ConversionOCF / Net Profit
3.14×
1.85×
TTM Free Cash FlowTrailing 4 quarters
$232.2M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYRG
MYRG
RVTY
RVTY
Q4 25
$114.8M
$182.0M
Q3 25
$95.6M
$138.5M
Q2 25
$32.9M
$134.3M
Q1 25
$83.3M
$128.2M
Q4 24
$21.1M
$174.2M
Q3 24
$35.6M
$147.9M
Q2 24
$22.7M
$158.6M
Q1 24
$7.7M
$147.6M
Free Cash Flow
MYRG
MYRG
RVTY
RVTY
Q4 25
$84.9M
$161.8M
Q3 25
$65.4M
$120.0M
Q2 25
$11.6M
$115.5M
Q1 25
$70.2M
$112.2M
Q4 24
$8.8M
$149.8M
Q3 24
$18.0M
$125.6M
Q2 24
$2.5M
$136.6M
Q1 24
$-18.1M
$129.7M
FCF Margin
MYRG
MYRG
RVTY
RVTY
Q4 25
8.7%
21.0%
Q3 25
6.9%
17.2%
Q2 25
1.3%
16.0%
Q1 25
8.4%
16.9%
Q4 24
1.1%
20.5%
Q3 24
2.0%
18.4%
Q2 24
0.3%
19.7%
Q1 24
-2.2%
20.0%
Capex Intensity
MYRG
MYRG
RVTY
RVTY
Q4 25
3.1%
2.6%
Q3 25
3.2%
2.6%
Q2 25
2.4%
2.6%
Q1 25
1.6%
2.4%
Q4 24
1.5%
3.4%
Q3 24
2.0%
3.3%
Q2 24
2.4%
3.2%
Q1 24
3.2%
2.7%
Cash Conversion
MYRG
MYRG
RVTY
RVTY
Q4 25
3.14×
1.85×
Q3 25
2.98×
2.97×
Q2 25
1.24×
2.49×
Q1 25
3.57×
3.03×
Q4 24
1.32×
1.84×
Q3 24
3.35×
1.57×
Q2 24
2.87×
Q1 24
0.41×
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MYRG
MYRG

Market Type Electrical Construction$442.6M45%
Market Type Transmission$330.3M34%
Market Type Distribution$200.6M21%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons